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RNAi is a powerful method for suppressing gene expression that
has tremendous potential for therapeutic applications. However,
because endogenous RNAi plays a role in normal cellular functions,
delivery and expression of siRNAs must be balanced with safety.
Here we report successful stable expression in primates of siRNAs
directed to chemokine (c-c motif) receptor 5 (CCR5) introduced
through CD34 hematopoietic stem/progenitor cell transplant.
After hematopoietic reconstitution, to date 14 months after trans-
plant, we observe stably marked lymphocytes expressing siRNAs
and consistent down-regulation of chemokine (c-c motif) receptor
5 expression. The marked cells are less susceptible to simian
immunodeficiency virus infection ex vivo. These studies provide a
successful demonstration that siRNAs can be used together with
hematopoietic stem cell transplant to stably modulate gene ex-
pression in primates and potentially treat blood diseases such as
HIV-1.
short-hairpin RNA  siRNA  rhesus macaque  gene therapy
s iRNAs recognize cognate mRNAs and induce sequencespecific RNA degradation through a highly conserved cellular
mechanism (1). Because siRNAs have the potential for thera-
peutic application, a number of vector systems have been
developed to express short-hairpin RNAs (shRNAs) to produce
siRNAs within mammalian cells in tissue culture and in animal
model systems (2–7). The results of these studies indicate that
expression of siRNAs can potentially be used to effectively
down-regulate gene expression in vivo for therapeutic purposes;
however, it is important to control for the negative effects of
expressing siRNAs in mammalian cells. Several recent studies
have reported adverse effects of expressing siRNAs in mamma-
lian cells, including induction of IFN responsive genes (8), global
changes of mRNA expression profiles caused by off-target
effects (9), and cytotoxic effects induced by microRNA
(miRNA) dysregulation (5). We reported cytotoxic effects of
shRNAs in human T lymphocytes as a result of overexpression
(10). Any adverse effects of siRNAs would be more problematic
in situations where siRNA expression is to be maintained in a
living organism for a long period, such as for intracellular
immunization against HIV-1 (11).
We selected the HIV-1 coreceptor, (c-c motif) chemokine
receptor 5 (CCR5), as a model to examine the feasibility of
long-term and stable down-regulation of cellular target gene by
siRNA. CCR5, is also an ideal target because it is essential for
infection by most strains of HIV-1, yet it is apparently dispens-
able in normal humans. Indeed, individuals who are homozygous
for the CCR5 delta 32 allele that prevents CCR5 cell surface
expression are resistant to HIV-1 infection but otherwise ap-
parently normal (12–15), and heterozygous individuals with
50% decrease in CCR5 surface expression have lower plasma
viral load and a substantially prolonged course of disease (14).
Recently, several CCR5 antagonists were examined in clinical
trials and resulted in reduction in plasma viral loads by 1.0–1.6
log10 copies/ml during treatment (16, 17). Although, CCR5
antagonists hold a great promise, there are drawbacks, such as
transient antiviral effects and drug toxicity. Because HIV-1
infects predominately T lymphocytes and macrophages, hema-
topoietic stem cell transplant could in theory be used to stably
express siRNA and down-regulate CCR5 in progeny cells that
are targets for HIV-1 infection.
We previously demonstrated that down-regulation of CCR5
by siRNA can protect primary human T lymphocytes in culture
from CCR5 tropic HIV-1 infection (4). Although effective
inhibition of HIV-1 infection was observed, we observed cyto-
toxicities in T lymphocytes that correlated with CCR5 siRNA
expression levels (10). By using the weaker H1 promoter, rather
than the U6 promoter, to express shRNA reduced toxicities,
however, the potency of the siRNAs was also attenuated. We
report here the identification of a potent and noncytotoxic
shRNA directed to CCR5 that stably down-regulates CCR5
when introduced via hematopoietic stem cell transplant.
Results
Given the cytotoxicities observed in primary human T lympho-
cytes with siRNAs expressed using the U6 promoter (10), we
screened a random library of shRNA directed to human CCR5
(huCCR5) sequences expressed using the H1 promoter within a
lentiviral vector. One shRNA sequence (CCR5 shRNA 1005)
was identified that had no obvious toxicities in human peripheral
blood (PB) T lymphocytes and was the most potent at inhibiting
CCR5 among shRNAs characterized to date (Fig. 1). Unlike
potent shRNAs expressed from the U6 promoter (10), expres-
sion of this shRNA from the H1 promoter did not alter the
growth kinetics of transduced T lymphocytes over a 12-day
period of culture (data not shown).
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The rhesus macaque hematopoietic stem/progenitor cell
transplant model is arguably the closest model to that of humans
(18). We tested the function and safety of this shRNA sequence
by lentiviral vector-mediated transduction of cytokine mobilized
PB rhesus CD34 cells followed by autologous transplant into
myeloablated rhesus macaques. We mutated a single mis-
matched nucleotide in the sequence of the huCCR5 shRNA so
that it would be 100% homologous to the corresponding rhesus
CCR5 target sequence. This rhesus CCR5 (rhCCR5) shRNA
sequence inhibited rhCCR5 expression but not huCCR5 (Fig.
2A). Similar to the homologous huCCR5 shRNA, there was no
apparent cytotoxicity (data not shown). CCR5 expression was
also inhibited by the expression of the rhCCR5 shRNA in
primary rhesus T lymphocytes (Fig. 2B).
Two rhesus macaques were subsequently transplanted with
autologous PB CD34 cells transduced with the rhCCR5–
shRNA lentiviral vector. The vector also expresses the EGFP
marker for tracking transduced cells. Recovery from transplant
was consistent with our previous studies (20, 21). Marking as
monitored by EGFP expressed from the vector increased over
time in PB granulocyte, monocyte, and lymphocyte lineages,
stabilizing at 6 months after transplant and monitored for 14
months (Fig. 3A).
Cell-surface expression of CCR5 was reduced in the EGFP
population relative to the EGFP population at all time points
assayed and ranged from 3- to 10-fold (Fig. 3 B and C). In
contrast, a control animal (2RC003) transplanted with vector
expressing EGFP but without shRNA (20) showed no evidence
of CCR5 down-regulation. Measurement of CCR5 mRNA levels
by RT-PCR showed 5- to 10-fold reduction of mRNA levels in
EGFP lymphocytes, consistent with the flow cytometric anal-
ysis of CCR5 cell-surface expression (data not shown).
Expression of siRNA was demonstrated by micro-Northern
blot analysis of lymphocytes from one transplanted rhesus
(RQ3570). The presence of a 22-nt band corresponding to the
antisense strand of CCR5 siRNA demonstrated processing of the
shRNA into the proper effector siRNA (Fig. 3D). More accurate
quantitation of the levels of siRNA in both animals by real-time
RT-PCR indicated expression of3 104 siRNA molecules per
EGFP cell in phytohemagglutinin (PHA)/IL-2-stimulated PB
T lymphocytes and 5-fold lower levels in nonstimulated PB
mononuclear cells. The level of siRNA in stimulated T lympho-
cytes is similar to the level of siRNA expressed from stimulated
rhesus-T lymphocytes transduced in vitro (data not shown).
Importantly, no apparent toxicity was observed despite expres-
sion of siRNA during hematopoietic cell differentiation over the
period of this study. The level of EGFP-marked cells increased after
transplant with normal kinetics and has remained stable over the
course of the study, 14 months to date. These results are in
accordance with our previous studies demonstrating stable EGFP
expression and marking in differentiated hematopoietic cells in
rhesus macaques transplanted with hematopoietic stem cells trans-
duced with lentiviral vectors (20–22). The flow cytometric profiles
of CD4, CD8, chemokine (c-x-c motif) receptor 4 (CXCR4),
CD45RA, and CD95(fas) are nearly identical for EGFP and
EGFP subpopulations [supporting information (SI) Fig. 5]. The
EGFP-marked lymphocytes respond normally in culture to PHA/
IL-2 stimulation with the same kinetics as nontransduced cells and
are maintained at the same frequency for up to 12 days (SI Fig. 6).
Over the same period of ex vivo culture, the reduction of CCR5
surface expression in the EGFP population persists even though
the overall expression of CCR5 in the EGFP population increases
from 5% to 35% of the cell population, because of IL-2-induced
CCR5 up-regulation on activated T cells, as described (23, 24) (SI
Fig. 7).
We tested the susceptibility of the PB lymphocytes (PBLs) to
simian immunodeficiency virus (SIVmac239) infection. Lympho-
cytes from animal ID RQ3570 were sorted for EGFP and
EGFP populations, activated with PHA/IL-2 for 2 days and
IL-2 for 2 days (total of 4 days), and infected with SIVmac239 at
a multiplicity of infection of 0.04. Both subpopulations prolif-
erated at comparable efficiencies. At the time of infection (d0),
the mean fluorescent intensity and percentage of CCR5 expres-
sion were 8 and 16.2 (Fig. 4A) and 4% and 9% (Fig. 4B) in the
Fig. 1. Identification of a potent shRNA against huCCR5. (A) CEM-NKR-CCR5 cells were transduced with lentiviral vectors expressing random shRNAs against
huCCR5 in 96-well plates, cultured for 3 days, and analyzed by flow cytometry for CCR5 expression in EGFP-expressing populations. Among the 400 shRNAs
screened, CCR5 shRNA(1005) reduced CCR5 more efficiently than our previously published CCR5-shRNA (13). The CCR5-shRNA (13) was selected based on the
initial criteria by Elbashir et al. (19). (B) Efficient reduction of endogenous CCR5 expression in human primary lymphocytes (huPBLs). PHA/IL-2-activated huPBL
were transduced with lentiviral vectors bearing shRNA(1005) and analyzed 8 days after infection by monoclonal antibody staining and flow cytometry for CCR5
expression in the EGFP population. Mock, no vector transduction; no shRNA, vector transduction without shRNA expression; N/A, not applicable. The
percentage of CCR5-expressing cells within the EGFP population (% CCR5 in EGFP) was calculated and is indicated on the top of each image. The percentage
number in each quadrant is also indicated.











EGFP and the EGFP population, respectively. The CCR5
cell surface expression increased overtime because of PHA/IL-2
stimulation. The EGFP population of cells produced 3-fold
lower levels of p27 SIV gag capsid antigen in the culture
supernatant than did the EGFP population at every time point
over the 9-day period of culture (Fig. 4C).
The degree of resistance to SIVmac239 was relatively modest;
however, the CCR5 levels significantly elevated ex vivo because
of PHA/IL-2 stimulation resulting in only a 2-fold difference in
CCR5 surface expression at the time of infection. In addition,
although CCR5 has been reported as the primary coreceptor for
SIVmac239 infection, SIVmac239 has also been reported to use
other coreceptors with lower efficiency (25). The use of other
coreceptors may contribute to SIV production in EGFP cells.
It is noteworthy that even 2-fold reductions in CCR5 surface
expression can slow disease progression, as in the case of CCR5
delta 32 heterozygote individuals (14).
Discussion
One advantage of stem cell gene therapy over lifetime antiret-
roviral drug therapy is that a successful gene therapy protocol
would be designed to be effective after a single treatment. When
applied therapeutically for HIV-1 disease, like gene therapy for
X-linked and adenosine deaminase deficiency SCIDs (26, 27),
we anticipate that the intense HIV-1-driven selection pressures
will result in selection over time of relatively HIV-1-resistant
cells. However, given the high rates of HIV production in
infected individuals and the ability of HIV to mutate to use other
coreceptors, effective therapeutic application of siRNAs for
HIV disease will likely involve combination with other ‘‘genetic
immunization’’ reagents directed against HIV. Given further
optimization, stable RNAi, introduced via hematopoietic stem
cell transplant has a potential to treat HIV-1 disease.
Our studies demonstrate that, given appropriate care in
selecting shRNAs, it is possible to produce siRNAs in vivo that
are both potent and safe for long-term therapy. Importantly, we
did not observe apparent adverse effects of siRNA on hemato-
poietic stem cell differentiation, T cell levels, subset phenotypes,
or by gross measures of lymphocyte activation. Continued
long-term followup of hematopoietic cell function and gene
expression profiles will be informative. These studies demon-
strate successful down-regulation of an endogenous gene using
RNAi through hematopoietic stem cell transplant in a primate.
Not only do these results provide the basis for a potential
therapeutic avenue for HIV-1 disease, but they also provide
evidence that RNAi could be used as a therapeutic modality for
other diseases.
Methods
Construction of CCR5 shRNA Library. We generated a random
shRNA library directed to huCCR5 sequences expressed using
an H1 promoter within a lentiviral vector by adapting the method
of enzymatic production of RNAi libraries from cDNAs
(EPRIL) (28). huCCR5 cDNA was PCR-amplified from pBA-
BE.CCR5 plasmid DNA (National Institutes of Health AIDS
research and reference reagent program) by using primer pairs
(5-GATGGATTATCAAGTGTCAAGTCCA-3) (5-GTCA-
CAAGCCCACAGATATTTCC-3) and KOD hot-start DNA
polymerase (Novagen, Madison, WI). The CCR5 cDNA was
partially digested by DNaseI (Qiagen, Chatsworth, CA) to
generate 100- to 200-bp DNA fragments. DNA fragments were
ligated to a hairpin adopter1 (Ad1) DNA linker containing an
MmeI restriction enzyme site (5-GTCGGACAATTGCGAC-
CCGCATGCTGCGGGTCGCAATTGTCCGAC-3). The li-
gated DNA fragments were then treated with T4 DNA polynu-
cleotide kinase (NEB, Beverly, MA) followed by Escherichia coli
DNA ligase treatment (NEB) to fill in a nick between the 5 end
of Ad1 and the 3 end of CCR5 DNA fragments. The Ad1-ligated
DNAs (40 nucleotides) were digested with MmeI (NEB) and
purified from a native PAGE gel. The purified DNA fragments
were ligated to an Ad2 linker (strand, 5-GGGGATCCCT-
TCGGTACTCCAGACCGTGAGTC-3) (strand, 5-TAC-
CGAAGGGATCCCCNN-3) and purified from a native PAGE
gel. The purified DNA fragments were treated with T4 polynu-
cleotide kinase (NEB) and T4 DNA ligase to fill a nick. The
Ad2-ligated by DNA fragments were subjected to a primer
extension reaction using primer (5-GACTCACGGTCTG-
GAGTACCGAAG-3) and BstDNA polymerase large fragment
(NEB), and the resulting products were purified from a PAGE
gel. The purified DNA fragments were digested with BpmI,
blunt-ended with Klenow fragment (NEB), digested with
BamHI, and ligated to pBShH1–5 plasmid DNA, which contains
a human H1 RNA polymerase III promoter and 4T termination
Fig. 2. Reduction of rhCCR5 by an shRNA(1005). An shRNA against rh-
CCR5(1005) was tested in rhCCR5-expressing 293T cells. Cells were transduced
with an SIV-based lentiviral vector bearing shRNA(1005) against rhCCR5 and
analyzed for CCR5 and EGFP expression by monoclonal antibody staining and
flow cytometry at 4 days after transduction. The rhCCR5 shRNA reduced
rhCCR5 expression in rhCCR5–293T cells but did not reduce huCCR5 in huCCR5-
expressing CCR5NKRCEM cells because of a single-nucleotide mismatch in
target sequence. Similarly, huCCR5 shRNA reduced huCCR5 but not rhCCR5.
(B) Reduction of CCR5 in primary rhesus macaque lymphocytes. Before a study
of lentiviral vector transduction and transplant of CD34 cells, PBLs from two
rhesus macaques (animal identifications, RQ3570 and RQ5427) were isolated,
PHA/IL-2-activated, and transduced with an SIV vector expressing shRNA
against rhCCR5(1005) in vitro. CCR5 expression was analyzed by flow cytom-
etry in EGFP cells. A vector expressing an shRNA against firefly luciferase was
used as a control. Mock, no vector transduction; N/A, not applicable. The
percentage of CCR5-expressing cells within EGFP population (%CCR5 in
EGFP) was calculated and is indicated on the top of each image. The
percentage number in each quadrant is also indicated.
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signal. The ligation mixture was introduced into E. coli (XL1
blue) by electroporation and plated on 2YT agar plate with 10
g/ml carbenicillin overnight. Approximately 8,000 colonies
were combined, and plasmid DNAs were prepared. The plasmid
DNAs were digested with BcgI, blunt-ended with T4 DNA
polymerase (NEB), and religated to remove excess DNA se-
quences. The religated plasmid DNAs were further treated with
MfeI to eliminate contamination of BcgI incompletely digested
plasmids and used to transform E. coli. Twenty clones of the
plasmid DNA were sequenced to confirm the randomness of
shRNA sequences targeting CCR5. After sequence confirma-
tion, shRNA expression units consisting of an H1 promoter,
shRNA sequence, and 4Ts termination signal were excised from
the pBShH1–5 plasmid DNAs by XbaI and XhoI digestion and
inserted into XbaI/XhoI sites of the FG12 lentiviral vector (4).
Lentiviral Vector Production and shRNA Library Screening. Four
hundred clones of vesicular stomatitis virus (VSV)-G
pseudotyped lentiviral vector were individually produced in
293T cells in 96-well plates. Vector supernatant from each well
was harvested at 48 h after transfection and used to infect
CCR5NKRCEM cells in 96-well plates. Reduction of CCR5
expression in EGFP cells was analyzed at 3 days after infection
by monoclonal staining against huCCR5 (2D7 APC; BD Bio-
sciences, San Jose, CA) and flow cytometric analysis.
shRNAs Against huCCR5 and rhCCR5. The target sequence of
huCCR5-shRNA(1005) identified from our shRNA library screen-
ing consisted of 5-GAGCAAGCUCAGUUUACACC-3. The
corresponding rhesus shRNA CCR5(1005) target sequence in
rhCCR5 mRNA is 5-GAGCAAGUUCAGUUUACACC-3. A
rhCCR5 shRNA expression unit was generated by inserting




GAGCT-5) into pBShH1–3 plasmid DNA. The rhCCR5 shRNA
sequence was confirmed by sequencing reaction. The target se-
quence of CCR5-shRNA (13) has been described (10).
SIVmac251-Based Lentiviral Vector Construction. To insert a rh-
CCR5 shRNA expression unit into an SIV-based vector for in
vitro transduction studies, XbaI and XhoI sites were created by
an oligo DNA insertion into a ClaI site in pSIV-R4SAW10,
which is derived from pSIV-games (29, 30). The rhCCR5 shRNA
expression unit was excised from the pBShH1–3 by XbaI and
XhoI digestion and inserted into the XbaI and XhoI site of
pSIV-R4SAW10.
To construct an SIV vector for animal transplant studies, we
inserted a SacII/XhoI DNA fragment containing the RhMLV
RNA polymerase II promoter sequence excised from pCS-Rh-
MLV-E plasmid DNA (31) into the ClaI/SalI sites of the SIV
vector (pSIV-RMES GAE) using an oligo DNA linker (strand
5-CGATACCCTAGGACGGCTGACGC-3, strand 5-
GTCGACCGTCCTAGGGTAT-3) (29). This resulted in vector
pSIV GAE RhMLV-E. EGFP expression has been shown to be
efficiently expressed in non-human primate lymphocytes by
using the RhMLV promoter (31). An XbaI/XhoI-digested DNA
fragment containing an H1 promoter-shRNA expression unit
was inserted into the AvrII and SalI sites in front of the RhMLV
promoter of the pSIV-GAE RhMLV-E vector, resulting in the
final pSIV GAE rhCCR5 shRNA RhMLV-E vector.
Lentiviral Vector Transduction. VSV-G pseudotyped retroviral/
lentiviral vector stocks were produced by calcium phosphate-
Fig. 3. In vivo vector marking, CCR5 down-regulation, and siRNA expression. (A) Stable EGFP marking in PB cells in transplanted animals. After CD34 cell
transplant, the percentage of EGFP expression was monitored in granulocyte (■), monocyte (), and lymphocyte (Œ) populations by flow cytometric analysis.
(B) Stable CCR5 reduction in EGFP lymphocytes. The percentage of CCR5 expression in EGFP (black bar) and in EGFP (gray bar) cells was monitored by flow
cytometry. Control animal 2RC003 was previously transplanted with a lentiviral vector bearing EGFP (20) but no shRNA expression unit. (C) A representative
CCR5/EGFP plot at 5 months after transplant. PB from transplanted macaques was stained for CCR5 and CCR5 and EGFP expression in lymphocyte population and
analyzed by flow cytometry. Based on the percentage of events in each quadrant (shown in each quadrant), the percentage of CCR5 expression in EGFP and
EGFP lymphocyte populations was calculated and is shown on the top of each image. (D) Detection of siRNA in rhesus macaque lymphocytes. The 22-nt
antisense-strand siRNA was detected by micro-Northern blot analysis in the small RNA fraction of PHA/IL-2-stimulated lymphocytes from an shRNA-transduced
animal (animal identification, RQ3570) but not in cells from control animal (animal identification, 2RC003).











mediated transfection of HEK-293 T cells, as previously de-
scribed. Briefly, HEK-293 T cells were cultured in Iscove’s
modified Eagle’s medium containing 10% FCS, 100 units of
penicillin, and 100 g/ml streptomycin. The pBabe-rhCCR5
retroviral vector was produced by cotransfecting vector plasmid,
the MLV packaging plasmid (pSV-psi-env-MLV) (32), and the
VSV-G expression plasmid. HIV vectors were produced by
cotransfecting vector plasmid, the HIV-1 lentiviral packaging
plasmids pRSVREV and pMDLg/pRRE, and pHCMVG. SIV-
based vector was produced by cotransfecting SIV vector, SIV
packaging vector pSIV15, pGREV, pSI-k-VPX plasmid DNAs
into HEK-293T cells by calcium phosphate transfection, as
described (29). Virus culture supernatants were harvested at day
2 after transfection and concentrated 300-fold by ultracentrifu-
gation. The concentrated virus stocks were titrated on HEK-293
T cells based on EGFP expression.
Cells. rhCCR5–293T was created by infecting HEK-293T cells
with a VSV-G pseudotyped pBabe-rhCCR5 retroviral vector
followed by puromycin selection (1 g/ml). CCR5-NKR-CEM
was obtained from the National Institutes of Health AIDS
reagents program. Human primary PB mononuclear cells were
isolated from leukopack by Ficoll-Paque PLUS (GE Healthcare
Life Sciences, Piscataway, NJ). Rhesus primary PB mononuclear
cells were isolated from PB by Ficoll-Paque PLUS.
Rhesus Macaque Cell Transduction and Transplant. Animals used in
this study were colony-bred rhesus macaques (Macaca mulatta)
maintained and used in accordance with guidelines of the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals (Department of Health and Human Ser-
vices publication no. NIH85-23). The protocol was approved by
the Animal Care and Use Committee of the National Heart,
Lung, and Blood Institute, National Institutes of Health, De-
partment of Health and Human Services. These animals were
free of specific pathogens (serologically negative for simian T
lymphotropic virus, SIV, simian retrovirus, and herpesvirus B).
CD34 hematopoietic stem/progenitor cells were mobilized into
the PB and purified as described (20). The PB CD34 cells from
the two animals (7  107 and 1  108 for animals RQ3570 and
RQ5427, respectively) were transduced ex vivo with the VSV-G
pseudotyped SIV rhCCR5 shRNA RhMLV-E vector at a mul-
tiplicity of infection of 2.4 once per day for 2 days in the presence
of stem cell factor (50 ng/ml) and IL-6 (50 ng/ml) in X-Vivo 10
Serum Free Medium with Gentamicin (50 g/ml; Cambrex Bio
Science, Walkersville, MD). Transduction efficiency was ana-
lyzed by quantitating EGFP expression by flow cytometry 64 h
after first transduction. Eighteen percent and 7.4% of the cells
were EGFP for animals RQ3570 and RQ5427, respectively.
The two animals received autologous transplants with 1.6  108
transduced PB CD34 cells. All animals received 10 Gy of
total-body gamma-irradiation as a 5-Gy fractionated dose given
on 2 consecutive days before transplantation (days 1 and 0,
with day 0 being the date of reinfusion) and supported with
antibiotic, blood, and fluid support accordingly.
Monoclonal Antibodies, Staining Procedures, and Flow Cytometric
Analysis. We used a whole-blood staining method to detect CCR5
on cell surface by monoclonal antibodies in PBLs (33). Briefly,
EDTA-treated whole blood was centrifuged, and plasma was
removed. Fifty microliters of packed blood was mixed with
monoclonal antibodies and stained at room temperature for 30
min, followed by ammonium chloride-mediated red blood cell
lysis, and fixed with 2% formaldehyde in PBS. For the staining
of ex vivo PHA/IL-2-stimulated cells, the cells (1  105) were
mixed with 5 l of anti-CCR5 monoclonal antibodies (2D7 for
human; 3A9 for rhesus) in 100 l of PBS in 2% FCS, incubated
at room temperature for 30 min, washed with PBS with 2% FCS,
and fixed with 2% formaldehyde in PBS. The monoclonal
antibodies used for this study included: anti-huCCR5 (2D7 APC,
556903; BD Biosciences), rhCCR5 (3A9 APC, 550586; BD
Biosciences), CD4 PerCP (550631; BD Biosciences), CD8PE
(555367; BD Biosciences), CXCR4 PE (555974; BD Bio-
sciences), CD45RO PE-Cy7 (337167; BD Biosciences), and
CD95 PE (556641; BD Biosciences). The stained cells were
analyzed by a FACScalibur (BD Biosciences) or a Cytomics
FC500 (Beckman Coulter, Fullerton, CA).
Cell Sorting. PB-derived mononuclear cells were isolated by
Ficoll-Paque PLUS (GE Healthcare Life Sciences), and EGFP
and EGFP lymphocyte populations were isolated by FACS
Aria cell sorter (BD Biosciences). The sorting purities of
EGFP and EGFP population were 92% and 96%, respec-
tively, as determined by flow cytometric analysis of the sorted
cells.
Small RNA Isolation. Small RNA fraction was isolated from
PHA/IL-2 stimulated rhesus monkey PBLs (4  108 cells) at
day 9 after stimulation by using the PureLink microRNA isola-
tion kit (Invitrogen, Carlsbad, CA) according to the manufac-
turer’s instructions.
Northern Blot Analysis of siRNA. Twenty-five micrograms of frac-
tionated small RNA was resolved on a 15% urea-acrylamide-
TBE gel (SequaGel; National Diagnostics, Atlanta, GA) and
electrotransferred to nylon membrane (GeneScreen Plus; NEN,
Waltham, MA) at 80 V for 1 h in 0.5 TBE. The membrane was
dried, UV cross-linked, and baked at 80°C for 1 h. Oligonucle-
otide probes (sense: GAG CAA GTT CAG TTT ACA CC;
antisense: GGT GTA AAC TGA ACT TGC TC) were labeled
by using Starfire oligos kit (Integrated DNA Technologies,
Fig. 4. Inhibition of SIV replication ex vivo. PBLs from RQ3570 at 13 months
after transplant were sorted for EGFP and EGFP population, stimulated
with PHA/IL-2 for 2 days and IL-2 for 2 days, and infected with SIVmac239. (A)
Mean fluorescent intensity (MFI) of CCR5 expression in EGFP sorted (black
bar) and EGFP sorted (gray bar) PHA/IL-2 activated lymphocyte. (B) The
percentage of CCR5 expression in EGFP and EGFP sorted lymphocytes.
CCR5 expression was monitored during ex vivo culture by flow cytometric
analysis and compared between EGFP (black bar) and EGFP sorted (gray
bar) lymphocyte populations. (C) SIV p27 production in EGFP and EGFP
sorted lymphocytes. After stimulation, 1  105 EGFP (‚) or EGFP (■) cells
were infected with 100 l of SIVmac239 at a multiplicity of infection of 0.04
(the infectious unit of the virus stock was 4104 ml by titrating on MAGI-CCR5
cells) for 1 h and monitored for p27 production for 11 days in culture super-
natant. The infection experiment was done in triplicate. The average p27
production in culture supernatant and error bar (standard deviation) are
shown.
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Coralville, CA) and [-32P] dATP (6,000 Ci/mmol; PerkinElmer,
Waltham, MA) according to the manufacturer’s instructions.
The probes were hybridized to the membranes at 37°C in
ULTRAhyb-Oligo (Ambion, Austin, TX) overnight. The mem-
brane was washed three times for 15 min at 37°C in 2 SSC/0.1%
SDS. Signal detection and analysis of Northern blots were
performed by exposing the blots to phosphorimaging plates
followed by analysis on a phosphorimager (Storm System; Mo-
lecular Dynamics, Sunnyvale, CA) by using synthetic rhCCR5
siRNA (GGU GUA AAC UGA ACU UGC UC; Sigma–Proligo,
St. Louis, MO) as a standard.
Real-Time RT-PCR Analysis. We used published primer pairs and
probes to detect rhCCR5 mRNA and 2 microglobulin (34).
Total RNA (100 ng) was isolated from sorted EGFP or
EGFP rhesus PBLs by TRIzol Reagent (Invitrogen) and
subjected to RT-PCR by using the Qiagen one-step RT-PCR kit
and the following conditions: 50°C, 30 min, and 55°C, 10 min for
reverse transcription reaction; 95°C, 15 min for reverse tran-
scription inactivation and activation of HotStarTaq DNA Poly-
merase; 50 cycles of 95°C, 15 sec, 55°C, 30 sec, and 60°C, 90 sec
for PCR. RNA standards for CCR5 and 2 microglobulin
mRNA quantitation were made by serial dilution of in vitro
transcribed rhCCR5 and 2 microglobulin RNAs by using T7
RNA polymerase (MEGAscript T7; Ambion).
RT-PCR Analysis of siRNA. We used a real-time stem–loop RT-PCR
method to quantitate the levels of the antisense strand of siRNA
against rhCCR5 (35). Total RNA (500 ng) was isolated from rhesus
PBLs by TRIzol reagent (Invitrogen) and subjected to reverse
transcription reaction (16°C, 30 min; 42°C, 30 min; 85°C, 5 min),
followed by PCR (95°C, 10 min, 1 cycle; 95°C, 15 sec and 58°C, 1
min, 50 cycles). Primer and probe sequences are as follows: reverse
transcription stem–loop primer, 5-GTCGTATCCAGTG-
CAGGGTCCGAGGTATTCGCACTGGATACGACAAG-
AGCAA-3; forward primer, 5-GCGCGGTGTAAACT-
GAAC-3; reverse primer, 5-GTGCAGGGTCCGAGGT;
probe, 6-FAM-TGGATACGACAAGAGCAA-MGB. A set of
serial diluted synthetic 22-nt antisense strand of siRNA against
rhCCR5 (GGU GUA AAC UGA ACU UGC UC; Sigma–
Proligo) was used as standard for quantitation.
SIV Production and Infection. The 5 and 3 halves of SIVmac239
plasmid DNAs linearized by SphI digestion were transfected into
HEK-293T cells. The virus produced was propagated in
CEMX174 cells. Infectious titer of virus stocks (4  104 infec-
tious units/ml) (p27 value 72 ng/ml) was determined on MAGI
CCR5 cells as described (36).
SIV Infection. Sorted EGFP or EGFP rhesus PBLs were stim-
ulated with PHA (5 g/ml; Sigma) and IL-2 for 2 days, PHA was
removed, and the cells were stimulated with IL-2 for another 2 days.
The cells (1  105) were infected with 100 l of SIVmac239
(multiplicity of infection of 0.04) for 1 h at 37°C, washed two times
with PBS with 2% FCS, washed one time with medium, and
resuspended in RPMI 20% FCS with IL-2 and cultured.
ELISA. The levels of SIV p27 core antigen in SIV-infected culture
supernatant were measured by using the COULTER SIV core
antigen assay according to the manufacturer’s instructions (cat-
alog no. 6604395; Beckman Coulter).
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